Donald J Buchsbaum

List of Publications by Citations

Source: https://exaly.com/author-pdf/8520635/donald-j-buchsbaum-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193 papers 6,469 citations

43 h-index

g-index

201 ext. papers

7,204 ext. citations

4.9 avg, IF

5.47 L-index

#	Paper	IF	Citations
193	The Wnt/Etatenin pathway in ovarian cancer: a review. <i>Gynecologic Oncology</i> , 2013 , 131, 772-9	4.9	313
192	Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. <i>Cancer Letters</i> , 2014 , 349, 8-14	9.9	231
191	A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. <i>Molecular Therapy</i> , 2000 , 2, 562-78	11.7	183
190	18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. <i>Cancer</i> , 1991 , 67, 1544-50	6.4	177
189	The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. <i>Journal of Biological Chemistry</i> , 2005 , 280, 11059-66	5.4	174
188	Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. <i>Oncogene</i> , 2003 , 22, 2034-44	9.2	145
187	Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1999 , 14, 451-63	3.9	119
186	Inhibition of Wnt/Etatenin pathway by niclosamide: a therapeutic target for ovarian cancer. <i>Gynecologic Oncology</i> , 2014 , 134, 112-20	4.9	118
185	ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. <i>Cancer Research</i> , 2013 , 73, 2368-78	10.1	113
184	An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. <i>Molecular Therapy</i> , 2001 , 4, 223-31	11.7	113
183	Recurrent read-through fusion transcripts in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 287-97	4.4	106
182	Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. <i>PLoS ONE</i> , 2011 , 6, e24792	3.7	103
181	Rationales, evidence, and design considerations for fractionated radioimmunotherapy. <i>Cancer</i> , 2002 , 94, 1332-48	6.4	103
180	Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. <i>Clinical Cancer Research</i> , 2003 , 9, 3731-41	12.9	103
179	Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 54, 1180-	.9 3	100
178	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. <i>Cancer Research</i> , 2016 , 76, 3978-88	10.1	96
177	Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. Journal of Medicinal Chemistry, 1999 , 42, 4919-24	8.3	88

(2016-2009)

176	Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. <i>Molecular Pharmacology</i> , 2009 , 76, 81-90	4.3	86
175	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. <i>Cancer Research</i> , 2002 , 62, 773-80	10.1	83
174	ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. <i>Cancer Biology and Therapy</i> , 2007 , 6, 548-54	4.6	78
173	Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 76-83	5.1	72
172	Catalase abrogates 🛘 apachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2110-20	6.1	71
171	Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. <i>Bioconjugate Chemistry</i> , 2003 , 14, 302-10	6.3	70
170	Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016 , 4, 390-9	12.5	66
169	Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. <i>Radiology</i> , 2002 , 223, 417-25	20.5	66
168	Effect of niclosamide on basal-like breast cancers. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 800-11	6.1	62
167	Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. <i>Clinical Cancer Research</i> , 2005 , 11, 8773-81	12.9	58
166	Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. <i>Journal of Immunology</i> , 2009 , 182, 7548-57	5.3	57
165	An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. <i>Molecular Therapy</i> , 2000 , 1, 545-54	11.7	57
164	Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. <i>Surgery</i> , 2007 , 141, 464-9	3.6	56
163	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 127, 420-5	4.9	55
162	Chapter sevenCancer treatment with gene therapy and radiation therapy. <i>Advances in Cancer Research</i> , 2012 , 115, 221-63	5.9	54
161	Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. <i>Cancer Research</i> , 2006 , 66, 8520-8	10.1	54
160	Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 4058-65	12.9	52
159	Niclosamide and its analogs are potent inhibitors of Wnt/Etatenin, mTOR and STAT3 signaling in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 86803-86815	3.3	48

158	KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. <i>Clinical and Experimental Metastasis</i> , 2010 , 27, 591-600	4.7	47
157	A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. <i>Gynecologic Oncology</i> , 2001 , 83, 432-8	4.9	47
156	Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget, 2017, 8, 8226-823	38 .3	47
155	Targeting the Wnt/Eatenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. <i>Laboratory Investigation</i> , 2016 , 96, 249-59	5.9	46
154	Experimental radioimmunotherapy. <i>Medical Physics</i> , 1993 , 20, 551-67	4.4	46
153	Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. <i>Gynecologic Oncology</i> , 2006 , 101, 46-54	4.9	45
152	Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?. <i>World Journal of Stem Cells</i> , 2014 , 6, 441-7	5.6	44
151	ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. <i>Journal of Biological Chemistry</i> , 2018 , 293, 984-994	5.4	44
150	Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. <i>Cancer Research</i> , 2008 , 68, 8369-76	10.1	43
149	Molecular targeted therapies for pancreatic cancer. <i>American Journal of Surgery</i> , 2008 , 196, 430-41	2.7	42
148	Ovarian cancer and the immune system - The role of targeted therapies. <i>Gynecologic Oncology</i> , 2016 , 142, 349-56	4.9	41
147	Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. <i>Cancer</i> , 2002 , 94, 1298-305	6.4	40
146	Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-NQN@N@tri s(acetic acid)cyclododecane (PA-DOTA). <i>Bioorganic and Medicinal Chemistry</i> , 1999 , 7, 2313-20	3.4	40
145	A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990 , 18, 1033-41	4	40
144	TRAIL receptor-targeted therapy. Future Oncology, 2006, 2, 493-508	3.6	39
143	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. <i>Molecular Oncology</i> , 2016 , 10, 1169-82	7.9	38
142	Synthesis of bombesin analogues for radiolabeling with rhenium-188. <i>Cancer</i> , 1997 , 80, 2354-2359	6.4	38
141	B7-H3-targeted Pb radioimmunotherapy of ovarian cancer in preclinical models. <i>Nuclear Medicine and Biology</i> , 2017 , 47, 23-30	2.1	37

(2007-2007)

140	Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. <i>Gynecologic Oncology</i> , 2007 , 105, 291-8	4.9	37
139	TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 3198-207	6.1	37
138	Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. Journal of Urology, 1990 , 144, 1288-92	2.5	37
137	Combined modality therapy with TRAIL or agonistic death receptor antibodies. <i>Cancer Biology and Therapy</i> , 2011 , 11, 431-49	4.6	36
136	Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. <i>Journal of Gastrointestinal Surgery</i> , 2004 , 8, 960-9; discussion 969-70	3.3	36
135	Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. <i>Journal of Surgical Research</i> , 2003 , 111, 274-83	2.5	36
134	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 680-8	6.1	35
133	Ovarian and cervical cancer patient derived xenografts: The past, present, and future. <i>Gynecologic Oncology</i> , 2015 , 138, 486-91	4.9	34
132	S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. <i>Scientific Reports</i> , 2015 , 5, 8453	4.9	34
131	Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 5535s-5543s	12.9	34
130	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. <i>Gynecologic Oncology Reports</i> , 2017 , 20, 81-86	1.3	31
129	Monoclonal antibodies in the treatment of pancreatic cancer. <i>Immunotherapy</i> , 2009 , 1, 223-9	3.8	31
128	Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. <i>Annals of Surgical Oncology</i> , 2007 , 14, 215	∂ -8	31
127	An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 1037-50	4	31
126	Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. <i>Molecular Therapy</i> , 2002 , 6, 190-8	11.7	31
125	Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. <i>Gynecologic Oncology</i> , 2014 , 132, 203-10	4.9	30
124	Effect of anti-DR5 and chemotherapy on basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 417-26	4.4	30
123	EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. <i>Journal of Surgical Research</i> , 2007 , 143, 20-6	2.5	30

122	Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. <i>Bioconjugate Chemistry</i> , 2004 , 15, 1264-74	6.3	30
121	Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 24, 329-34	4	30
120	Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. <i>Clinical Cancer Research</i> , 2008 , 14, 2180-9	12.9	29
119	Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 507-16	4	29
118	Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 59, 2-10	4	29
117	Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2009 , 113, 384-90	4.9	28
116	Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993 , 25, 629-38	4	28
115	Preferential Inhibition of Wnt/ECatenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	27
114	Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 5643s-5645s	12.9	27
113	Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. <i>Nuclear Medicine and Biology</i> , 2001 , 28, 135-44	2.1	27
112	Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. <i>Cancer Gene Therapy</i> , 1999 , 6, 209-19	5.4	27
111	Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. <i>Oncology Reviews</i> , 2017 , 11, 332	4.3	26
110	Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. <i>Nuclear Medicine and Biology</i> , 2018 , 58, 67-73	2.1	26
109	Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. <i>Molecular Cancer Research</i> , 2011 , 9, 403-17	6.6	26
108	TRAIL-receptor antibodies as a potential cancer treatment. Future Oncology, 2007, 3, 405-9	3.6	25
107	Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 3130-9	6.1	24
106	Pretargeted radioimmunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, S57-9	4	24
105	Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. <i>Molecular Therapy</i> , 2004 , 10, 1059-70	11.7	24

(2018-2016)

104	Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer. <i>Proteomics</i> , 2016 , 16, 516-31	4.8	24
103	DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. <i>Molecular Imaging and Biology</i> , 2011 , 13, 94-103	3.8	23
102	Overcoming TRAIL resistance in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2010 , 119, 157-63	4.9	23
101	Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2845-54	6.1	23
100	Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. <i>Clinical Cancer Research</i> , 2005 , 11, 8180-5	12.9	23
99	Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 437-45	4.4	22
98	Experimental radioimmunotherapy. Seminars in Radiation Oncology, 2000, 10, 156-67	5.5	22
97	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. <i>Oncotarget</i> , 2017 , 8, 44159-44170	3.3	22
96	Experimental tumor targeting with radiolabeled ligands. <i>Cancer</i> , 1997 , 80, 2371-2377	6.4	21
95	Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. <i>Seminars in Nuclear Medicine</i> , 2004 , 34, 32-4	1 <i>ē</i> ∙4	21
94	De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent. <i>Bioconjugate Chemistry</i> , 2002 , 13, 317-26	6.3	21
93	The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. <i>Gynecologic Oncology</i> , 2012 , 125, 226-30	4.9	20
92	Modulation of antitumor immunity with histone deacetylase inhibitors. <i>Immunotherapy</i> , 2017 , 9, 1359-1	33.782	20
91	Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 42, 817-22	4	20
90	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. <i>Gynecologic Oncology</i> , 2007 , 106, 614-21	4.9	20
89	High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 866-75	6.1	20
88	Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005 , 20, 502-13	3.9	20
87	Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	19

Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors 86 induced to express the gastrin-releasing peptide receptor by an adenoviral vector. Cancer, 1997, 80, $2419-2424^{19}$ Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta 6.4 85 19 dose-rate nonuniformity. Cancer, 1994, 73, 912-8 Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Cancer, 1994, 84 6.4 19 73, 999-1005 Loss of tumor suppressor Merlin results in aberrant activation of Wnt/Eatenin signaling in cancer. 83 19 3.3 Oncotarget, 2016, 7, 17991-8005 A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal 82 6.4 18 antibodies. Cancer, 1994, 73, 769-73 Niclosamide Analogs for Treatment of Ovarian Cancer. International Journal of Gynecological Cancer 81 3.5 17 , **2015**, 25, 1377-85 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo 80 17 4.9 human cervical cancer model. Gynecologic Oncology, 2008, 108, 591-7 Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 16 79 5.8 **2011**, 301, L79-90 Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic 78 adenocarcinoma cell viability in vitro and growth in vivo. Journal of Gastrointestinal Surgery, 2006, 16 3.3 10, 1291-300; discussion 1300 Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular Imaging, 2011, 16 3.7 77 Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Molecular Imaging, 2011, 76 15 3.7 10, 7290.2010.00040 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA 75 4.1 15 vaccination generates enhanced therapeutic anti-tumor effects. Vaccine, 2008, 26, 4314-9 Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND 74 5.4 15 COMPUTATIONAL STUDY. Journal of Biological Chemistry, 2016, 291, 12862-12870 Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases 73 3.3 14 cytotoxicity to cholangiocarcinoma cells. Journal of Gastrointestinal Surgery, 1998, 2, 283-91 Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and 6.4 72 14 their biodistribution in tumor-bearing nude mice. Cancer, 1994, 73, 808-15 Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 71 14 111-indium. European Journal of Nuclear Medicine and Molecular Imaging, 1985, 10, 398-402 Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic 70 5.4 14 cancer cells. Journal of Biological Chemistry, 2021, 296, 100034 A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer 69 2.6 13 effect in a systemic nude mouse orthotopic model. Pancreas, 2012, 41, 789-96

(2018-2009)

68	Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 814-9	3.5	13
67	Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci. <i>Bioconjugate Chemistry</i> , 1999 , 10, 18-23	6.3	13
66	Role of nanotechnology and gene delivery systems in TRAIL-based therapies. <i>Ecancermedicalscience</i> , 2016 , 10, 660	2.7	13
65	The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/Etatenin signaling in cancer cells. <i>PLoS ONE</i> , 2013 , 8, e58102	3.7	12
64	Gene therapy for the treatment of cancer. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 275-	88 3.9	12
63	Localization of an 125 I-labeled rat transplantation antibody in tumors carrying the corresponding antigen. <i>Experimental Biology and Medicine</i> , 1972 , 139, 1185-8	3.7	12
62	Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. <i>Current Opinion in Oncology</i> , 1999 , 11, 187-90	4.2	12
61	Histone deacetylase inhibition promotes intratumoral CD8 T-cell responses, sensitizing murine breast tumors to anti-PD1. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 2081-2094	7.4	12
60	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 175-188	7.4	12
59	Gene expression imaging with radiolabeled peptides. <i>Annals of Nuclear Medicine</i> , 2004 , 18, 275-83	2.5	11
58	Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 950-8	4	11
57	A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 35, 165-72	4	11
56	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer, 2018, 124, 46	5 <i>7</i> .466	5611
55	Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1053-60	4.6	10
54	A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. <i>Pancreas</i> , 2010 , 39, 913-22	2.6	10
53	Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. <i>Bioconjugate Chemistry</i> , 1993 , 4, 194-8	6.3	10
52	Inhibition of the Wnt/Etatenin pathway enhances antitumor immunity in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920913798	5.4	10
51	Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 6216-6230	4.7	9

50	Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3059-65	3.1	9
49	Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. <i>Gynecologic Oncology</i> , 2011 , 121, 193	3 <u>4</u> 9	9
48	Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. <i>Clinical and Translational Medicine</i> , 2017 , 6, 11	5.7	8
47	Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. <i>Molecular Imaging and Biology</i> , 2014 , 16, 85-94	3.8	8
46	Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. <i>Cancer</i> , 1997 , 80, 2567-2575	6.4	8
45	A sensitivity study of micro-TLDs for in vivo dosimetry of radioimmunotherapy. <i>Medical Physics</i> , 1991 , 18, 1195-9	4.4	8
44	Radiotargeted gene therapy. <i>Journal of Nuclear Medicine</i> , 2005 , 46 Suppl 1, 179S-86S	8.9	8
43	SRI36160 is a specific inhibitor of Wnt/Etatenin signaling in human pancreatic and colorectal cancer cells. <i>Cancer Letters</i> , 2017 , 389, 41-48	9.9	7
42	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. <i>Translational Oncology</i> , 2020 , 13, 100776	4.9	7
41	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/Etatenin transcription, cancer cell growth, and tumor immunity. <i>Drug Discovery Today</i> , 2020 , 25, 1521-1527	8.8	7
40	Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model. <i>Journal of Visualized Experiments</i> , 2015 ,	1.6	7
39	Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. <i>Journal of the Egyptian National Cancer Institute</i> , 2015 , 27, 205-15	1.9	6
38	Pazopanib combined with radiation: in vivo model of interaction. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014 , 29, 247-50	3.9	6
37	In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. <i>Orl</i> , 2009 , 71, 1-5	2	6
36	Gene delivery and gene therapy of prostate cancer. Expert Opinion on Drug Delivery, 2006, 3, 37-51	8	6
35	Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent. <i>Bioconjugate Chemistry</i> , 2002 , 13, 327-32	6.3	6
34	Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins. <i>International Journal of Radiation Oncology Biology Physics</i> , 1987 , 13, 1701-12	4	6
33	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. <i>MedComm</i> , 2020 , 1, 121-	12.8	6

32	Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 2285-2294	4.7	5
31	Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1193-6	3.5	5
30	Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol. <i>Bioconjugate Chemistry</i> , 1997 , 8, 766-71	6.3	5
29	Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. <i>Analytical Biochemistry</i> , 2002 , 301, 189-99	3.1	5
28	Introduction: radiolabeled antibody tumor dosimetry. <i>Medical Physics</i> , 1993 , 20, 499-501	4.4	5
27	New azomycin acyclonucleoside. Synthesis and biodistribution of radiohalogenated analogues in tumor-bearing mice. <i>Journal of Heterocyclic Chemistry</i> , 1993 , 30, 1351-1355	1.9	5
26	STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2020 , 80, 4355-4370	10.1	5
25	The use of retinoids in ovarian cancer: a review of the literature. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 191-8	3.5	4
24	A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. <i>Molecular Imaging and Biology</i> , 2016 , 18, 325-33	3.8	3
23	Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. <i>Radiotherapy and Oncology</i> , 2011 , 101, 183-9	5.3	3
22	Synthesis and biodistribution of peptide based 99mTc/186Re-MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1997 , 12, 55-62	3.9	3
21	Single-photon emission computed tomography imaging with a humanized, Apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1392-1398	4.6	3
20	Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodies. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1992, 43, 1387-91		3
19	B7-H3-targeted Radioimmunotherapy of Human Cancer. Current Medicinal Chemistry, 2020 , 27, 4016-40	3,8 3	3
18	Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer". <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 7615	8.3	2
17	Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003 , 18, 239-47	3.9	2
16	Cancer gene therapy 2009 , 589-612		2
15	CD38 pretargeted RIT of B-cell tumors. <i>Blood</i> , 2018 , 131, 589-590	2.2	1

14	Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies. <i>International Journal of Peptide and Protein Research</i> , 1996 , 48, 79-86		1
13	Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1997 , 12, 375-84	3.9	1
12	Localization of radiolabeled antibody in SVT2 tumor increases with immunosuppression of the host. <i>Experimental Biology and Medicine</i> , 1982 , 171, 56-64	3.7	1
11	Radionuclide Dosimetry and Radioimmunotherapy of Cancer 2000 , 21-55		1
10	Cancer gene therapy 2003 , 583-613		1
9	Dosimetry of Radiolabeled Antibodies. <i>Medical Radiology</i> , 1995 , 365-384	0.2	1
8	Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1077, 87-113	3.6	1
7	Invited commentary: targeting of 125I-labeled B lymphocyte stimulator. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 434-6	8.9	1
6	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone <i>Advances in Cancer Research</i> , 2022 , 153, 131-168	5.9	O
5	Retraction notice to "SRI36160 is a specific inhibitor of Wnt/-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48]. <i>Cancer Letters</i> , 2018 , 422, 131	9.9	
4	Cytosine Deaminase/5-Fluorocytosine Molecular Cancer Chemotherapy 2010 , 219-242		
3	In Reply to Dr. Speer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, 1274	4	
2	A robust summarize-regress procedure for tissue-specific pharmacokinetics. <i>Journal of Biopharmaceutical Statistics</i> , 2000 , 10, 251-64	1.3	
1	Drugs in clinical trials & future directions 2011 , 84-95		